A comparison study of exosomes and biomimetic nanovesicles for brain tumor drug delivery

Exosomes (Exos) are promising vehicles for brain drug delivery due to nanosize and the ability to breach the blood–brain barrier (BBB). But the low yield of natural exosomes limits its application for nanomedicine. The generation of bioinspired nanovesicles (BNVs) that mimicking Exos is attractive, but there is a lack of comparative evaluation of Exos and BNVs. Researchers from Central South University, China performed the first head-to-head comparison study of Exos and BNVs for brain tumor drug delivery. They show that BNVs derived from brain-derived endothelial cells are competent alternative nanocarrier to natural exosomes. The drug-loading capacity of Exos and BNVs are similar, but the yield of BNVs is substantially higher (500-fold) than Exos. Doxorubicin (DOX)-loaded BNVs (BNV/DOX) and DOX-loaded Exos (Exo/DOX) showed similar pharmacokinetic profiles and prolonged circulation od DOX. Despite inconsistent mechanisms, BNV/DOX can across the BBB, and exhibit suppression effects similar to Exo/DOX on the progress of glioblastoma (GBM) in zebrafish and in vivo subcutaneous and orthotopic xenografts mice models, with minimal systemic toxicity. Findings from this head-to-head comparison study indicate that autologous BNVs is a effective alternative of Exos for brain tumor nanomedicine.

Wu JY, Li YJ, Hu XB, Huang S, Luo S, Tang T, Xiang DX. (2021) Exosomes and biomimetic nanovesicles-mediated anti-glioblastoma therapy: A head-to-head comparison. J Control Release 336:510-521. [abstract]

Leave a Reply

Your email address will not be published. Required fields are marked *